within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01ED01_Crizotinib;

model Crizotinib
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.43,
    Cl = 1.6805555555555555e-05,
    adminDuration = 600,
    adminMass = 250 / 1000000,
    adminCount = 1,
    Vd = 1.21,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.007899999999999999,
    Tlag = 13.98,
    Vdp = 4.89,
    k12 = 3.472222222222222e-05,
    k21 = 3.472222222222222e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Crizotinib</td></tr><tr><td>ATC code:</td><td>L01ED01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>250</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1210</td><td>L</td></tr>
    <tr><td>clearance:</td><td>60.5</td><td>L/hr</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Crizotinib is an orally administered small-molecule inhibitor of ALK (anaplastic lymphoma kinase), ROS1, and MET tyrosine kinases used for the treatment of ALK-positive and ROS1-positive non-small cell lung cancer (NSCLC). It is approved for use in adults with advanced or metastatic NSCLC.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult cancer patients, oral administration, typical dose 250 mg twice daily, analyzed as a two-compartment model with first-order absorption.</p><h4>References</h4><ol><li><p>Gibson, EG, et al., &amp; Stewart, CF (2021). Population pharmacokinetic analysis of crizotinib in children with progressive/recurrent high-grade and diffuse intrinsic pontine gliomas. <i>Cancer chemotherapy and pharmacology</i> 88(6) 1009–1020. DOI:<a href=\"https://doi.org/10.1007/s00280-021-04357-4\">10.1007/s00280-021-04357-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34586478/\">https://pubmed.ncbi.nlm.nih.gov/34586478</a></p></li><li><p>Gupta, N, et al., &amp; Venkatakrishnan, K (2021). Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer. <i>Clinical pharmacokinetics</i> 60(2) 235–247. DOI:<a href=\"https://doi.org/10.1007/s40262-020-00929-4\">10.1007/s40262-020-00929-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32816246/\">https://pubmed.ncbi.nlm.nih.gov/32816246</a></p></li><li><p>Greengard, E, et al., &amp; Weigel, BJ (2020). Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children&#x27;s Oncology Group phase 1 consortium study (ADVL1212). <i>Cancer chemotherapy and pharmacology</i> 86(6) 829–840. DOI:<a href=\"https://doi.org/10.1007/s00280-020-04171-4\">10.1007/s00280-020-04171-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33095287/\">https://pubmed.ncbi.nlm.nih.gov/33095287</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01ED01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Crizotinib;
